TGTX vs TLX: fair value comparison
TG Therapeutics, Inc. and Telix Pharmaceuticals Limited · Updated 2026-10-19
TGTX is still awaiting a full valuation verdict under our six-validated-windows standard. TLX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, TGTX currently ranks higher by quality score.
| TGTX | TLX | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $53.97 | $10.69 |
| 12-month range | $26.94–$59.06 | $6.41–$12.83 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #129 of 301 Healthcare | #130 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Moderate | Moderate |
| Margin trend | Contracting | Stable |
| Revenue growth | Strong | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: TGTX fair value analysis · TLX fair value analysis